Sunesis Pharmaceuticals (SNSS) Tops Q1 EPS by 6c

Sunesis Pharmaceuticals (NASDAQ: SNSS) reported Q1 EPS of ($0.21), $0.06 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $200 thousand versus the consensus estimate of $200 thousand.

For earnings history and earnings-related data on Sunesis Pharmaceuticals (SNSS) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• TJX Cos. (TJX) Tops Q2 EPS by 3c, Beats on Revenue; Offers FY27 EPS Guidance
• Hershey (HSY) PT Lowered to $206; RBC Capital: 'Struggling to See a Near Term Positive Inflection'